Table 2 Patients’ Characteristics in 75 patients
Parameter | Total (%)(N = 75) | Typical response (%)(N = 24) | Typical progression (%)(N = 15) | iUPD (%)(N = 9) | Stable Disease (%)(N = 25) | Pseudoprogression (%)(N = 2) | P Value |
|---|---|---|---|---|---|---|---|
Gender | Â | Â | Â | Â | Â | Â | 0.06 |
 Male | 48 (64) | 12 (50) | 10 (66) | 9 (100) | 15 (60) | 2 (100) |  |
 Female | 27 (36) | 12 (50) | 5 (33) | 0 | 10 (40) | 0 |  |
Mean age ± SD, y | 48.8 ± 14.15 | 46.2 ± 15.6 | 48.3 ± 16.27 | 56.3 ± 8.18 | 48.84 ± 12.75 | 49 ± 19.79 | 0.51 |
Clinical T stage (cT) | Â | Â | Â | Â | Â | Â | 0.28 |
 T1–3 | 36 (48) | 13 (54) | 3 (20) | 5 (55) | 14 (56) | 1 (50) |  |
 T4 | 24 (32) | 7 (29) | 8 (53) | 4 (44) | 4 (16) | 1 (50) |  |
 Not investigated | 15 (20) | 4 (16) | 4 (26) | 0 | 7 (28) | 0 |  |
Clinical N stage (cN) | Â | Â | Â | Â | Â | Â | 0.98 |
 0 | 11 (14) | 4 (16) | 2 (13) | 3 (33) | 2 (8) | 0 |  |
 N1 | 21 (28) | 8 (33) | 5 (33) | 2 (22) | 4 (16) | 2 (100) |  |
 N2 | 27 (36) | 8 (33) | 4 (26) | 4 (44) | 11 (44) | 0 |  |
 Not investigated | 16 (21) | 4 (16) | 4 (26) | 0 | 8 (32) | 0 |  |
Clinical M stage (cM) | Â | Â | Â | Â | Â | Â | 0.94 |
 0 | 23 (30) | 7 (29) | 2 (13) | 4 (44) | 9 (36) | 1 (50) |  |
 1 | 38 (50) | 13 (54) | 9 (60) | 5 (55) | 10 (40) | 1 (50) |  |
 Not investigated | 14 (18) | 4 (16) | 4 (26) | 0 | 6 (24) | 0 |  |
Mean treatment course ± SD |  |  |  |  |  |  | 0.007 |
8.6 ± 7.3 | 12.2 ± 8.9 | 8.7 ± 4.5 | 3.0 ± 1.2 | 6.8 ± 6.6 | 11.5 ± 9.2 |  | |
Mismatch Repair Status | Â | Â | Â | Â | Â | Â | 0.04 |
 Mismatch Repair-Proficient (pMMR) | 41 (54) | 12 (50) | 7 (46) | 9 (100) | 12 (48) | 1 (50) |  |
 Mismatch Repair-Deficient (dMMR) | 22 (29) | 9 (37) | 2 (13) | 0 | 10 (40) | 1 (50) |  |
 Not investigated | 12 (16) | 3 (12) | 6 (40) | 0 | 3 (12) | 0 |  |
Histologic types | Â | Â | Â | Â | Â | Â | 0.72 |
 Adenocarcinoma | 58 (77) | 20 (83) | 9 (60) | 9 (100) | 18 (72) | 2 (100) |  |
 Mucinous adenocarcinoma | 8 (10) | 2 (8) | 2 (13) | 0 | 4 (16) | 0 |  |
 Signet ring cell carcinoma | 1 (1) | 0 | 1 (6) | 0 | 0 | 0 |  |
 Other | 8 (10) | 2 (8) | 3 (20) | 0 | 3 (12) | 0 |  |
KRAS status | Â | Â | Â | Â | Â | Â | 0.54 |
 Wild-type | 21 (28) | 6 (25) | 3 (20) | 4 (44) | 7 (28) | 1 (50) |  |
 Mutated | 16 (21) | 6 (25) | 2 (13) | 1 (11) | 7 (28) | 0 |  |
 Not investigated | 38 (50) | 12 (50) | 10 (66) | 4 (44) | 11 (44) | 1 (50) |  |